Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/GILD
icon
Up to 4x
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Gilead Sciences, Inc. (GILD) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Gilead Sciences (GILD) trades at $153.65, down 1.63% with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported strong Q1 and Q2 2026 earnings beats despite a negative EPS in Q2, with revenue growth from $29.44B in 2025 to projected $30.5B in 2026. Recent developments include expanded HIV prevention drug access in Latin America through a PAHO partnership.
GILD presents a compelling growth story with analyst consensus favoring Buy (65.52%) and a $153.13 price target near current levels. However, negative net income margin (-10.64%) and high EV/EBITDA (120.21) signal valuation concerns. Key risks include execution of pipeline advancements and competitive pressures in biopharmaceuticals.
Read full analysis

Key Stats

  • Market Cap
    $193.67B
  • Volume
    7,762,328
  • Sector
    Health
  • 52W High
    $157.37
  • 52W Low
    $117.88
  • Typical Hold Time
    113 Days
  • Enterprise Value
    $216.74B
  • Div Yield
    2.1%
  • Trading Activity
    79% Sell | 21% Buy
$153.15
52W Low: $117.88
28 Oct 2025
52W High: $157.37
15 Oct 2026

Track Gilead Sciences, Inc. (GILD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $117.88 and a high of $157.37, highlighting its annual price range. Buy and sell Gilead Sciences, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Most Recent News

Content is generated by Aura AI

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
1 hour ago
Xbiotech Inc.
Bullish
news icon
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
2 hours ago
Danny Green
Neutral
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Silence Therapeutics jumps 125% after $1.3B acquisition deal with Merck KGaA

Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...

Market News
3 hours ago
Stuart Mooney
Bullish
news icon
Silence Therapeutics jumps 125% after $1.3B acquisition deal with Merck KGaA
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $193.67B
  • Volume
    7,762,328
  • Sector
    Health
  • 52W High
    $157.37
  • 52W Low
    $117.88
  • Typical Hold Time
    113 Days
  • Enterprise Value
    $216.74B
  • Div Yield
    2.1%
  • Trading Activity
    79% Sell | 21% Buy
$153.15
52W Low: $117.88
28 Oct 2025
52W High: $157.37
15 Oct 2026

Track Gilead Sciences, Inc. (GILD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $117.88 and a high of $157.37, highlighting its annual price range. Buy and sell Gilead Sciences, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!